All In Biotech

Drug Trial Radar · NCT01556997

Perindopril Amlodipine for the Treatment of Hypertension

Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension

Last checked: Nov 20, 2026Latest source record: Sep 28, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 837 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

837

Actual

Start

Feb 2012

Primary completion

Feb 2013

Study completion Feb 2013

Sponsor

Lead sponsor
Symplmed Pharmaceuticals LLCIndustry
Sponsor type
Industry
First posted
Mar 19, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the safety and efficacy of a fixed-dose combination drug compared to two other drugs (monotherapies) in controlling hypertension.

Conditions

  • Essential Hypertension

Interventions

  • XOMA 985Drug

    PERa/AMLb capsule taken once daily by mouth for six weeks

  • Amlodipine BesylateDrug

    AMLb capsule taken once daily by mouth for six weeks

  • Perindopril ErbumineDrug

    PERe capsule taken once daily by mouth for six weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to End of Treatment in the Mean Seated Trough Cuff Diastolic Blood Pressure (DBP).Time frame: Day 0 to Day 42

Locations

48 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Huntsville, Alabama

  • Site not named

    Muscle Shoals, Alabama

  • Site not named

    Glendale, Arizona

  • Site not named

    Greenbrae, California

  • Site not named

    Los Angeles, California

  • Site not named

    Santa Ana, California

  • Site not named

    Denver, Colorado

  • Site not named

    DeLand, Florida

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Palm Harbor, Florida

  • Site not named

    Port Orange, Florida

  • Site not named

    Marietta, Georgia

  • Site not named

    Gurnee, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Wichita, Kansas

  • Site not named

    Louisville, Kentucky

  • Site not named

    Metairie, Louisiana

  • Site not named

    Auburn, Maine

  • Site not named

    Baltimore, Maryland

  • Site not named

    Olive Branch, Mississippi

  • Site not named

    Butte, Montana

  • Site not named

    Berlin, New Jersey

  • Site not named

    Greensboro, North Carolina

  • Site not named

    Hickory, North Carolina

  • Site not named

    Raleigh, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Columbus, Ohio

  • Site not named

    Kettering, Ohio

  • Site not named

    Lyndhurst, Ohio

  • Site not named

    Marion, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Tulsa, Oklahoma

  • Site not named

    Eugene, Oregon

  • Site not named

    Mt. Pleasant, South Carolina

  • Site not named

    Simpsonville, South Carolina

  • Site not named

    Bristol, Tennessee

  • Site not named

    Austin, Texas

  • Site not named

    Corpus Christi, Texas

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.